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Abstract 18
Swine dysentery (SD) is a mucohaemorrhagic colitis of pigs resulting from infection of  19
the large intestine with the anaerobic intestinal spirochaete Brachyspira hyodysenteriae. 20
Whole-cell bacterin vaccines are available to help control SD, but their performance has  21
been inconsistent. This study aimed to use a reverse vaccinology approach to identify B.  22
hyodysenteriae proteins for use as recombinant vaccine components. Nineteen open  23
reading frames (ORFs) predicted to encode potential vaccine candidate molecules were  24
identified from in silico analysis of partial genomic sequence data. The distribution of  25
these ORFs amongst strains of B. hyodysenteriae was investigated by PCR, and widely  26
distributed ORFs were cloned. The products were screened with a panel of immune pig  27
sera, and from these a subset of conserved, immunogenic proteins was selected. Mice  28
immunized intramuscularly with these recombinant proteins developed specific systemic  29
antibody responses to them, and their sera agglutinated B. hyodysenteriae cells in vitro. In  30
a pilot experiment, eight pigs were vaccinated twice intramuscularly with a combination  31
of four of the proteins. The pigs developed antibodies to the proteins, and following  32
experimental challenge only one developed SD compared to five of nine non-vaccinated  33
control pigs. Although these differences in incidence were not significant, they indicated a  34
trend towards protection using the recombinant proteins as immunogens. This study  35
demonstrates that the reverse vaccinology approach has considerable potential for use in  36
developing novel recombinant vaccines for SD.  37
38
Keywords: Brachyspira hyodysenteriae; Spirochaete; Swine dysentery; Reverse  39
vaccinology; Recombinant protein 40
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1. Introduction 42
The anaerobic intestinal spirochaete Brachyspira hyodysenteriae is an important  43
enteric pathogen. Infection of growing and fattening pigs results in swine dysentery (SD),  44
a severe mucohaemorrhagic colitis that causes significantly disruption to production  45
(Hampson et al., 2006). Although the incidence and severity of SD can be reduced in  46
infected herds by using antimicrobials, strains of B. hyodysenteriae that are resistant to  47
various key antimicrobial agents are increasingly being encountered (Duinhof et al.,  48
2008). The availability of an effective vaccine for SD would be an important alternative or  49
supplement to the use of antimicrobials for control of the disease.  50
To date vaccines for SD have largely been based on inactivated whole cells of B.  51
hyodysenteriae, but these often fail to confer a satisfactory degree of protection against  52
infection, and do not provide adequate cross-protective immunity against strains of  53
different serogroups (Hampson et al., 2006). Efforts have been made to identify B.  54
hyodysenteriae proteins for use in subunit vaccines, but vaccination with a recombinant 38  55
kDa flagellar protein failed to prevent colonization in experimentally infected pigs (Gabe  56
et al., 1995). On the other hand, vaccination with a recombinant 29.7 kDa outer membrane  57
lipoprotein (Bhlp29.7) resulted in partial protection, with fewer animals developing  58
disease than occurred in the control groups (La et al., 2004). This result provided evidence  59
for the potential usefulness of recombinant proteins as subunits for SD vaccines, and  60
encouraged the current investigation.  61
“Reverse vaccinology” uses a combination of bioinformatics analysis of whole  62
genomic sequence data and laboratory screening to identify novel vaccine candidates for  63
bacterial pathogens (Rappuoli, 2001). This approach was first successfully applied to  64
Neisseria meningitidis serogroup B, for which conventional strategies have failed to  65
provide an efficacious vaccine (Pizza et al., 2000). 66Page 4 of 28
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The aim of the present study was to investigate the use of the reverse vaccinology  67
approach to select potential vaccine candidates for B. hyodysenteriae, and to test a small  68
number of these for efficacy in pigs.  69
70
2. Materials and methods 71
2.1. Spirochaete strains and growth 72
A total of 27 well-characterized B. hyodysenteriae strains representing the major  73
serogroups were obtained from the collection held at the Australian Reference Centre for  74
Intestine Spirochaetes (ARCIS), School of Veterinary and Biomedical Sciences, Murdoch  75
University. These comprised 19 strains from Australia, four from the USA, three from  76
Canada, and one from the Netherlands. The strains were thawed and grown at 38°C in  77
Kunkle’s pre-reduced anaerobic broth containing 2% (v/v) foetal bovine serum and 1%  78
(v/v) ethanolic cholesterol solution (Kunkle et al., 1986). 79
80
2.2. Permissions 81
The experimental work with animals was conducted with the approval of the  82
Murdoch University Animals Ethics Committee. All procedures were carried out under  83
Australian National Health and Medical Research Council guidelines. 84
85
2.3. Genomic sequencing and in silico analysis 86
The genome of Australian B. hyodysenteriae strain WA1 (ATCC 49526) was  87
sequenced using a shotgun sequencing approach at the Australian Genome Research  88
Facility, University of Queensland, Australia, with an approximate six times coverage.  89
The program Phred was used for fragment assembly (Ewing et al., 1998), with subsequent  90
viewing using Consed (Gordon et al., 1998). Identification of open reading frames (ORFs)  91Page 5 of 28
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was carried out using Glimmer and GeneMark (Lukashin and Borodovsky, 1998; Salzberg  92
et al., 1999). The identified ORFs were given a temporary designation starting with ORF-,  93
with the encoded protein identified with the same number but starting with P-. For  94
selected ORFs, searches for functional assignments were conducted using BlastP  95
(ftp.ncbi.nlm.nih.gov) performed with the non-redundant protein database (Altschul et al.,  96
1997). Protein domains were assigned by searching against Pfam (Bateman et al., 2002) 97
and the Conserved Domain Database (CDD) (Wheeler et al., 2001). The cut-off E-value  98
was set to 10
-7 as a default, and proteins with lower E-values were considered genuine  99
homologies. Cellular localization predictions for each ORF were carried out as follows:  100
prediction of the presence and location of signal peptides in the N-terminal 70 amino acids  101
of an ORF, using SignalP (Version 3.0, http:// www.Cbs.dtu.dk/services/SignalP/)  102
(Bendtsen et al., 2004); prediction of protein localization sites in Gram-negative bacteria  103
using PSORTb (version 2.0, http://www.psort.org/psortb/) ( Nakai, 2000; Gardy et al.,  104
2005); identification of lipoprotein signatures by the Lipop program of the PSORT  105
package (Nakai, 2000), and SpLip (Setubal et al., 2006) for specifically predicting  106
spirochaetal lipoproteins (obtained from Setubal and Haake, Virginia Bioinformatics  107
Institute, USA); and recognition of membrane-spanning regions, using TMpred  108
(http://www.ch.embnet.org/software/TMPRED_form.html) (Hofmann et al., 1999).  109
Theoretical molecular weights and isoelectric points were calculated using the Pepstats  110
program (Emboss).  111
112
2.4. PCR amplification and sequencing 113
Pairs of primers that annealed to internal regions of each of 19 selected coding  114
sequences were designed (supplementary table S1), and were used for PCR amplification  115Page 6 of 28
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from the B. hyodysenteriae strains. If a gene could be amplified from more than 90% of  116
the strains examined, it was selected for cloning.  117
DNA sequencing was conducted using a pair of flanking primers (Supplementary  118
table 2) that annealed to regions external to the coding sequences of the putative genes.  119
For ORF-N17, which was greater than 1600 base pairs (bp), internal primers were used to  120
cover the missing regions. For sequencing, whole ORFs were amplified from the genomes  121
of 6-7 B. hyodysenteriae strains. The PCR products were purified using the UltraClean up  122
Kit (Mo Bio Laboratories, Solana Beach, CA, USA), according to the manufacturer’s  123
instructions. Sequencing of the PCR products was performed using the ABI PRISM
TM 124
Dye Terminator cycles Sequencing Ready Reaction Mix (PE Applied Biosystems, Foster  125
City, CA, USA). Sequence results were edited and compiled using SeqEd v1.0.3 (PE  126
Applied Biosystems), then translated into amino acid sequence using the BioEdit  127
Sequence Alignment Editor (North Carolina State University). The nucleotide and  128
translated protein sequences for all the genes were compared to produce a pair-wise  129
identity matrix using Clustal W (Thompson et al., 1994).  130
131
2.5. Cloning and expression of recombinant protein 132
ORFs were amplified from B. hyodysenteriae strain WA1 using primers encoding  133
restriction endonuclease recognition sites for cloning into the E. coli expression vector  134
pTrcHisA (Invitrogen, Carlsbad, CA, USA). If an N-terminal signal peptide for secretion  135
was predicted, the corresponding nucleotide sequence was excluded. Among the selected  136
coding sequences, ORF-H17, encoding a large protein with a predicted size of 111.05 kDa  137
was amplified and cloned in two smaller sub-fragments (ORF-H17 N-terminus and ORF- 138
H17 C-terminus) to facilitate subsequent expression and purification. Constructs were  139
confirmed by sequencing using vector (pTrcHisA)-specific primer (FP: 5’- 140Page 7 of 28
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GAGGTATATATTAATGTATCG-3’ and RP: 5’- TCTTCTCTCATCCGCCAAAAC-3’).  141
Recombinant proteins were expressed as inclusion bodies in E. coli JM109 in Luria- 142
Bertani broth supplemented with 100 mg/l ampicillin and 1mM isopropyl-B- 143
thiogalactopyranoside. Most of the proteins were purified under denaturing conditions  144
using nickel nitrilotriacetic acid (Ni-NTA) affinity chromatography (Qiagen GmbH),  145
according to the manufacturer’s instructions. Two proteins (P-H8 and P-H12) were  146
soluble in the cytoplasm and were purified under native conditions. Protein concentrations  147
were determined using the Bradford Protein assay (Biorad, Madison, WI, USA). The  148
recombinant protein elutions were dialyzed, resuspended in phosphate buffer saline (PBS)  149
and emulsified 1:1 (vol:vol) with Freunds Incomplete Adjuvant (Difco Laboratories) for  150
mouse immunizations. 151
152
2.6. Serological assays 153
For each of the relevant recombinant proteins, five female C3A/HeJ mice of 5-6  154
weeks of age, housed in one cage, were immunized intramuscularly with 100 μg of the  155
protein, twice at a two-week interval. Two weeks later the mice were individually  156
euthanazed by gassing with methoxyfluorane followed by cervical dislocation. Serum was  157
obtained by heart puncture at necropsy.  158
For Western blot analysis, 10 μg of recombinant protein was separated by SDS- 159
PAGE and electro-transferred to a 0.2 μm nitrocellulose membrane. Nineteen porcine  160
serum samples were obtained from the collection at ARCIS, and were used to detect the  161
expression and antigenicity of recombinant proteins. The sera included: N1-N3 from  162
healthy grower pigs; M1-M3 from pigs immunized with whole cell bacterins of B.  163
hyodysenteriae, B. pilosicoli and B. innocens respectively; S1-S5 from individual pigs  164
experimentally infected with B. hyodysenteriae that developed clinical SD, and had  165Page 8 of 28
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lesions of SD at post-mortem; S6-S9 from individual infected pigs with a serological  166
conversion to B. hyodysenteriae using a whole cell ELISA; S10-S13 from four pigs  167
recovered from SD. The sera were used at a 1:100 dilution. Bound antibody was detected  168
with an alkaline phosphatase (AP)-conjugated anti-swine lgG (Sigma; diluted 1:5000).  169
Pre- and post-immunization sera (diluted 1:100) from experimental mice or pigs also were  170
examined by Western blotting using 10 μg recombinant protein and 15 μg of protein from  171
a B. hyodysenteriae whole cell preparation. The secondary antibody was anti-mouse lgG- 172
AP for mouse sera (Sigma; diluted 1: 5000). 173
The mouse sera raised against each antigen also were examined for their capacities  174
to agglutinate B. hyodysenteriae. Normal mouse serum and serum from a pig  175
hyperimmunized with B. hyodysenteriae B78
T bacterin were used as the negative and  176
positive controls respectively. The agglutination test was performed in 96 well U-bottom  177
plates with 5 × 10
9 cells of B. hyodysenteriae strain WA1 resuspended in 50 μl PBS,  178
carried out essentially as previously described (Diarra et al., 1994). Antiserum was serially  179
diluted in 50 μl PBS (1:100 to 1: 6800) and added to each well containing spirochaetes.  180
The last column was left without serum as a control. The plates were incubated overnight  181
at 37°C. The antibody titer was expressed as the reciprocal of the highest dilution of serum  182
showing a definite positive pattern (flat sediment) as compared with the pattern of the  183
negative control (smooth dot) in the center of the well. 184
185
2.7. Immunization and challenge of pigs 186
Eighteen female pigs weaned at 3 weeks of age were purchased from a commercial  187
SD-free herd in Western Australia, and transported to an isolation animal house at  188
Murdoch University. The animals were weighed, ear-tagged and randomly assigned to  189
two groups of 9: group 1, an unvaccinated control group; group 2, the experimental  190Page 9 of 28
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vaccine group. One pig from group 2 subsequently became lame and was removed. The  191
pigs were fed ad libitum on a commercial pelleted weaner diet that did not contain any  192
antimicrobial agents. On arrival, and prior to infection, rectal faeces were collected and  193
subjected to selective anaerobic culture for Brachyspira species. The pig challenge studies  194
were performed essentially as described by La et al. (2004), starting two weeks after the  195
pigs were purchased. The pigs in the vaccinated group were injected intramuscularly with  196
2 ml of a vaccine containing 0.5 mg of each of four recombinant proteins emulsified in a  197
commercial water-in-oil adjuvant (Emulsigen; MUP Laboratories Inc., Ralston, NE,  198
USA). Four weeks later they received a second immunization using the same dose and  199
route. Three weeks later, all pigs were inoculated via stomach tube with approximately  200
10
10 active viable cells of B. hyodysenteriae strain BW1 in 100 ml of Kunkle’s broth.  201
Experimental challenge was repeated daily over five days.  202
The pigs were evaluated daily for the presence of diarrhoea, mucus and/or blood in  203
the faeces, depression and/or anorexia. The consistency of the faeces also was assessed  204
during rectal swabbing for bacteriological examination. Pigs were weighed prior to the  205
first vaccination (“pre-bleed”), just prior to the second vaccination (“pre-boost”), prior to  206
the first day of challenge (“pre-infection”) and weekly thereafter. The animals were  207
removed from the experiment if they developed clinical signs, and consequently thereafter  208
their weights were not recorded. Serum samples were taken from the anterior vena cava  209
pre-vaccination, pre-boost, pre-infection and at post-mortem.  210
Necropsy was performed as previously described (La et al., 2004). For ethical  211
reasons, dysenteric pigs were killed within 24 hours of the first appearance of diarrhoea  212
containing blood and mucus. The remaining pigs were killed 28 days after the last day of  213
experimental infection. At post-mortem, the large intestine was opened and examined for  214
gross pathological changes. Swabs were taken from the wall of the caecum and mid-colon  215Page 10 of 28
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and plated on selective agar. Fresh tissue from these two areas was placed into 10% (v/v)  216
formalin, and subsequently 4 μm sections were cut and stained with haematoxylin and  217
eosin and with Steiner silver stain.  218
219
2.8. Detection of B. hyodysenteriae 220
Bacteriology swabs were used to collect rectal faeces from each pig every 2-3  221
days, and to swab the mucosal surface of the colonic and caecal walls at post-mortem. The  222
swabs were used to inoculate selective agar plates and incubated as previously described  223
(La et al., 2004). The presence of low flat spreading growth of spirochaetes on the plate,  224
and any haemolysis around the growth was recorded. Suspected areas of spirochaete  225
growth were resuspended in PBS, and examined under a phase contrast microscope at 400  226
× magnification. Spirochaetes were confirmed as B. hyodysenteriae on the basis of strong  227
β-haemolysis on the plates, microscopic morphology and results of a NADH oxidase (nox)  228
PCR of cell growth from the plates. The primers and PCR conditions used have been  229
described previously (La et al., 2003).  230
231
2.9. ELISA for serum antibodies 232
Enzyme-linked immunoabsorbent assays (ELISA) were used to determine lgG and  233
lgM responses in the pig sera, as previously described (La et al., 2004). Briefly, microtitre  234
plates (Sarstedt Technologies, SA, Australia) were coated with the respective purified  235
recombinant proteins (0.5 μg/ml) or a whole-cell (WC) preparation of B. hyodysenteriae 236
strain WA1 (1 μg/ml) in 0.1 M carbonate buffer (pH 9.6). Pig sera were diluted 200-fold  237
in 100 μl of PBS-T containing 0.01% skim-milk powder. The conjugates used were goat  238
anti-swine lgG or lgM conjugated with horseradish peroxidase (HRP: Southern  239
Biotechnology, Birmingham, AL, USA) and the substrate was K-Blue TMB substrate  240Page 11 of 28
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(ELISA Systems, Brisbane, Australia). The colour reaction was stopped after 10 min by  241
adding 1 M sulphuric acid. The optical density (OD) was measured at 450 nm on a  242
microplate reader (Biorad Model 3550-UV).  243
244
2.10. ELISA for colonic lgA and lgG 245
Extraction and assaying of colonic lgA and lgG used a method adapted from Rees  246
et al. (1989). The colonic epithelium was rinsed to remove digesta, stripped off with a  247
scalpel blade and resuspended in 4 ml of PBS containing 1% (w/v) bovine serum albumen  248
fraction V, 2 mM phenylmethylsulphonyl fluoride, 1 mM ethylenediaminetetracetic acid  249
and 0.2% (w/v) sodium azide. The suspensions were vortexed for 1 min at 4°C to pellet  250
the debris. The supernatant was diluted 1:2 with PBS-T, and 100 μl was used for the  251
ELISAs. These were performed as for the serum ELISAs, except a goat anti-swine lgA- 252
HRP (1: 5000 dilution, Southern Biotechnology) was used to detect mucosal lgA. 253
254
2.11. Disease scoring 255
Pigs were scored positive for clinical signs of SD if they had diarrhoea with fresh  256
blood and/or mucus in their faeces. Intestinal lesions were considered typical of SD if  257
haemorrhage, excess mucus, fibrin, and/or necrosis were observed in the caecum and/or  258
colon. Lesion severity was classified as: Mild, patchy reddening in ≤1/3 colon; Severe,  259
lesions in > 1/3 colon with blood, oedema and excess mucus. SD was defined as the  260
presence of both positive clinical signs and typical colonic lesions. Pigs that had mild  261
localized lesions in the colon at post-mortem, but did not have clinical signs, were scored  262
as being “healthy”. Similarly, pigs with mild diarrhoea but no colonic lesions were  263
recorded as “healthy”. 264
265Page 12 of 28
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2.12. Statistic analysis 266
Microsoft Excel and SPSS for windows 14.0 were used for statistic analysis. Body  267
weights and ELISA values were expressed as the arithmetic mean and standard deviation,  268
and statistical differences between the groups were assessed using one-way ANOVA.  269
Faecal excretion of B. hyodysenteriae, incidence of SD, and the association between onset  270
of disease and the antibody levels were evaluated using Fisher’s exact test. The number of  271
pig sampling days in which cultures were positive or negative for B. hyodysenteriae also  272
was compared for the groups. Linear regression was used to compare body weights and  273
antibody levels, and the Pearson correlation coefficient was calculated to determine the  274
association of ELISA reactivity between recombinant proteins and the whole-cell  275
preparation. Significance was accepted at the 5% level.  276
277
3. Results 278
3.1 Identification of vaccine candidates from in silico analysis 279
Initially 19 ORFs encoding predicted proteins with various functions were selected  280
for further evaluation. These were grouped as predicted lipoproteins, proteases and toxins,  281
flagellar-associated proteins and membrane proteins. Details of the ORFs and their  282
vaccine candidate group are given in Supplementary table 3, together with their GenBank  283
accession numbers.  284
285
3.2. Conservation of the candidate genes among B. hyodysenteriae strains 286
Using gene-specific PCR assays, 17 of the 19 genes were found in >90% of the B.  287
hyodysenteriae strains tested. ORF-H28 and ORF-H29 demonstrated 34.9% and 73.9%  288
distribution respectively, and were discarded. 289
290Page 13 of 28
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3.3. Cloning and expression of recombinant proteins 291
Of the 19 molecules that were cloned (including the remaining 17 full ORFs, and  292
both fragments of ORF-H17), 14 (74%) were successfully expressed as determined by  293
Western blot detection with an anti-6x His tag antibody. ORF-H14, ORF-H16, ORF-H20,  294
ORF-H26 and ORF-H27 failed to express even after optimization of the time-course,  295
alteration of isopropyl -D-thiogalactopyranoside concentration and expression  296
temperature, and using another expression system (pET19b and pQE30) (data not shown).  297
Highly expressing colonies were used for protein purification. 298
299
3.4. Serological reactivity of the recombinant proteins 300
Of the 14 purified proteins screened for reactivity by immunoblotting with a range  301
of porcine sera, seven (P-H7, P-H8, P-H12, P-H17, P-H17 C-terminal, P-H34 and P-H42),  302
derived from six genes, were found to be immunoreactive. Examples are shown in Fig. 1.  303
These protein products also reacted with the hyperimmune pig anti-B. pilosicoli and B.  304
innocens sera, and showed cross-reactivity with normal pig serum. All seven molecules  305
produced antibody responses in mice, and the sera were specific in that they recognized  306
whole-protein extracts of B. hyodysenteriae preparations with native proteins of the  307
correct size (data not shown). Sera from the non-immunized mice did not recognize any of  308
the components tested. 309
Figure 1 about here 310
The mouse antisera produced following vaccination with the candidate proteins all  311
agglutinated the B. hyodysenteriae cells in a dose-dependent manner. Sera raised against  312
P-H7 and P-H12 agglutinated the cells to a dilution of 400, serum against P-H8 and P-H42  313
agglutinated to 800, and serum against P-H34, P-H17 and the C-terminal of P-H17  314Page 14 of 28
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agglutinated to a dilution of 1600. The positive hyperiummune serum agglutinated to a  315
3200 dilution, while the negative control serum did not agglutinate the spirochaetes. 316
317
3.5. Nucleotide sequence conservation  318
The full ORFs of the six genes from which the seven immunoreactive molecules  319
originated all had 98-100% nucleotide sequence identity and 99-100% predicted amino  320
acid identity amongst the set of B. hyodysenteriae strains from which they were amplified.  321
322
3.6. Final selection of vaccine proteins 323
On the basis of ease of expression and purification, products from four of the six  324
ORFs were selected for use in the prototype vaccine. These were P-H7, P-H17 (C- 325
terminal), P-H34 and P-H42. The product from the C-terminal of ORF-H17 was used  326
rather than the whole protein, as it was equally as immunoreactive.  327
328
3.7. Body weights of experimental pigs  329
The body weights of the pigs showed no significant differences between the  330
groups over the course of the experiment.  331
332
3.6. Systemic antibody responses 333
Systemic IgG antibody levels in the pigs against the different antigens are  334
summarized in Figure 2. The overall patterns of response with time were similar whether  335
recombinant antigens or whole cell extracts were used as ELISA plate coating antigens.  336
The non-vaccinated pigs showed a clear trend to have increased circulating IgG antibodies  337
against the recombinant proteins or whole cell proteins through to pre-infection, with  338
further larger increases following infection. Increases in IgM levels occurred in the same  339Page 15 of 28
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manner (data not shown). For the vaccinated pigs serum lgG and lgM levels to all antigens  340
and the whole cell preparation showed increases after the first vaccination, but a  341
significant response was not detected after the second vaccination, and in most cases  342
infection with live B. hyodysenteriae did not further increase the antibody responses.  343
Indeed, in some of the pigs, there was a trend for antibody levels to decline after the  344
second vaccination, but the change was not statistically significant. Mean antibody levels  345
to P-H7 were lower in the vaccinated pigs than in the infected control pigs. Western blot  346
analysis of swine serum from the vaccinated group confirmed that the systemic antibody  347
response was primary directed against the candidate proteins of B. hyodysenteriae used in  348
the study. The serum antibody levels of individual pigs did not significantly correlate with  349
whether or not they developed disease. 350
   Figure 2 about here 351
3.7. Colonic antibody response 352
The local antibody responses in the colon of the pigs at slaughter are summarized  353
in Table 1. In the vaccinated pigs the local IgA and IgG responses to the candidate  354
proteins, except to IgG in the case of P-H7, were all significantly higher than in the  355
control group. IgA but not IgG responses were also higher with the whole cell preparation.  356
The local antibody levels did not significantly correlate with presence or absence of  357
disease at post-mortem. 358
Table 1 about here 359
3.8. Faecal excretion of B. hyodysenteriae 360
All rectal swabs were negative for B. hyodysenteriae and other Brachyspira  361
species on arrival and prior to experimental infection. For the control pigs, B.  362
hyodysenteriae excretion was first detected in two pigs (C1 and C8) 10 days after the end  363
of experimental infection, and these two developed SD within a few days. Six of the other  364Page 16 of 28
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seven pigs in the group shed B. hyodysenteriae in their faeces, and two developed SD. The  365
other pig was culture positive at post-mortem. For the vaccinated pigs, the first faecal  366
samples positive for B. hyodysenteriae occurred at 10 days in two pigs (V1 and V4),  367
however they subsequently did not re-excrete nor develop SD. Five of the other six pigs  368
shed B. hyodysenteriae at some time, but only one developed SD. Overall, the numbers of  369
positive faecal samples in the two groups were 26/76 and 22/78, and these differences  370
were not significant (P = 0.6). 371
372
3.9. Development of clinical signs, and findings at post-mortem 373
The post-mortem findings are outlined in Table 2. The appearance of clinical signs  374
of SD always coincided with the prior occurrence of positive faecal cultures, although in  375
some pigs positive cultures were not followed by disease development. Four of the nine  376
control pigs developed clinical signs of SD, and severe mucohaemorrhagic colitis was  377
found at post-mortem examination. Another pig (C2) in the control group had diarrhoea  378
for two days, and at necropsy there were mild colonic lesions. This also was scored  379
positive, making the number of positive animals 5/9 (56%) for the control group. The  380
median onset of clinical signs in the control group was 14 (9, 10, 14, 17 21) days after  381
challenge. For the vaccinated group, one pig developed diarrhoea 22 day after challenge,  382
and had mild localized mucohaemorhagic colitis in the upper third of the colon at post- 383
mortem. Another pig had mild lesions in the middle half of the colon at post-mortem, but  384
had not shown clinical signs. The other six pigs remained healthy, and had no colonic  385
lesion at post-mortem, although five of them had B. hyodysenteriae in their large  386
intestines. The incidences of disease in the two groups were recorded as 5/9 and 1/8,  387
respectively, and this difference was not significant (P = 0.13).  388
Table 2 about here 389Page 17 of 28
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4. Discussion 390
This study explored the use of a reverse vaccinology approach for identifying  391
potential candidates for use in a recombinant B. hyodysenteriae vaccine. Reverse  392
vaccinology typically utilizes a complete genome sequence, and usually favours putative  393
secreted toxins and surface exposed membrane proteins or lipoproteins as vaccine targets  394
(Mohavedi and Hampson, 2008). At the time the current pilot study commenced only a  395
partial genome sequence was available, and the choice of potential vaccine candidates was  396
relatively limited. As a result, only a small number (19) of proteins that were either  397
putative lipoproteins, toxin-like proteins, flagellar-associated proteins or membrane- 398
associated proteins (both inner and outer membrane) were selected for further screening.  399
Analysis of distribution and sequence conservation amongst these vaccine  400
candidates was important as the heterogeneity of some proteins among bacterial isolates  401
can cause problems with cross-protection, which limits their usefulness as vaccines  402
(Tappero et al., 1999). Most of the putative genes were present in all the B. hyodysenteriae  403
strains examined, and for the six genes that survived the full screening process, their  404
predicted amino acid sequences in a subset of strains were ≥99% identical to the sequence  405
of the corresponding protein from strain WA1. This suggested that if the selected vaccine  406
candidates were shown to confer protection against one B. hyodysenteriae strain they  407
potentially would provide cross-protection against other strains. 408
All the selected recombinant proteins reacted strongly with the panel of sera from  409
naturally and experimentally infected pigs, suggesting that the corresponding antigens are  410
expressed in vivo. Some reactivity with sera from healthy pigs was present, and this was  411
consistent with previous findings that sera from normal pigs are reactive with B.  412
hyodysenteriae surface antigens (Wannemuehler et al., 1988). The antigens also reacted  413
with hyperimmune pig sera against B. pilosicoli and B. innocens. This was not  414Page 18 of 28
Accepted Manuscript
18
unexpected, as structural proteins in related organisms are likely to share common  415
epitopes that would produce cross-reacting antibodies when used as immunogens.  416
The final experimental vaccine was formulated to contain four candidate proteins  417
for which there was good immunogenicity data, and which were easy to produce. They  418
were combined in the vaccine to reduce the work required to evaluate each protein  419
separately, as well as to potentially improve the protection that would be obtained.  420
Vaccination of mice with the individual proteins generated specific antibodies to the  421
recombinant proteins, and sera from the mice agglutinated B. hyodysenteriae cells. The  422
latter activity provided supporting evidence that the vaccine would induce antibodies with  423
relevant activities against the whole spirochaete.  424
Unexpectedly, in the pig trial the non-vaccinated pigs developed increasing  425
systemic lgG and lgM levels to all antigens as their body weights increased, although the  426
highest levels were achieved after bacterial challenge. The reason for these increases was  427
unclear as the experimental pigs came from a herd with no reported history of SD or  428
isolation of B. hyodysenteriae, and Brachyspira species were not isolated from the animals  429
before the experiment started. It seems possible that the presence of such cross-reacting  430
antibodies could help to explain the relatively small number of control pigs that developed  431
SD (5/9). 432
The vaccinated pigs developed a primary antibody response, but significant  433
secondary responses were not produced, and in most cases experimental challenge did not  434
increase the antibody levels further. This unusual pattern of serological response might be  435
attributed to the use of several proteins in combination, or could be due to the high dose  436
rates used in the vaccine. It did not appear to be a prozone effect, as further serial dilutions  437
of a selection of these sera did not change the relative results (data not shown). At the  438
level of the colon, local lgA and lgG levels to the corresponding recombinant proteins, and  439Page 19 of 28
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to the whole cell preparation in the case of IgA, were higher in the vaccinated pigs than in  440
the control group at post-mortem. The colon and/or caecum of the majority of pigs in both  441
groups were colonized at post-mortem, but the number of spirochaetes present was not  442
evaluated. In future studies it would be useful to quantify the spirochaetes to determine  443
whether such local antibodies reduced the extent of colonization, potentially to levels  444
where disease does not develop. 445
Following experimental challenge, some animals began to shed B. hyodysenteriae  446
in their faeces around one week after inoculation. The onset and total amount of shedding  447
in the two groups over the experimental period were not significantly different, but this  448
may have been influenced by the fact that four shedding pigs were removed from the  449
control group before the end of the experimental period, and so did not contribute further  450
to the shedding score. Removal of these animals also meant that they could not contribute  451
to a cumulative clinical score. In the control group shedding was more likely to be  452
followed by disease, and again it is possible that the use of quantitative methods might  453
have revealed that the vaccinated pigs were shedding fewer spirochaetes than the control  454
animals that developed disease. 455
The fact that only one (13%) pig receiving the experimental vaccine developed  456
clinical signs of SD suggested that the vaccine was conferring some protection, even  457
though statistical significance was not achieved. It would be useful to repeat this trial with  458
more pigs to try to achieve more clear-cut differences between the groups. Other evidence  459
suggesting the potential usefulness of the vaccine was the fact that dysenteric pigs in the  460
control group had severe and extensive lesions in their large intestines at post-mortem,  461
whilst the vaccinated pig with clinical signs showed localized lesions, and another pig  462
only had mild colonic lesions and no clinical signs. If these differences were translated to  463Page 20 of 28
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the farm situation, such a vaccine would be helpful in reducing SD-associated production  464
losses.  465
In conclusion, this study provided evidence that reverse vaccinology is a useful  466
approach to antigen selection for use in recombinant vaccines for SD. In future work  467
additional B. hyodysenteriae proteins should be examined, and it would be helpful to  468
evaluate different protein concentrations, adjuvants and vaccine delivery methods. The  469
supporting vaccine trials should use larger groups of animals and utilize a more  470
quantitative approach to assess the relative level of protection achieved. For reasons of  471
animal ethics, pigs need to be removed when they become ill, so it may not be possible to  472
develop a clinical scoring method. However, quantitation of spirochaetal load should  473
provide useful additional information about vaccine efficacy. 474
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Figure legends 557
Fig. 1. Western blot analysis of the recombinant proteins, performed using sera from pigs  558
naturally or experimentally infected with SD, or immunized with Brachyspira spp.  559
bacterins. Lane M, molecular mass markers (kDa); Lanes 1-3, normal pig sera. Lanes 4-6,  560
sera from pigs hyperimmunized with B. hyodysenteriae, B. pilosicoli and B. innocens,  561
respectively. Lanes 7-11, serum from individual experimentally infected SD pigs. Lanes  562
12-15, sera from pigs showing seroconversion to B. hyodysenteriae in a whole cell– 563
ELISA. Lanes 16-19, individual sera from pigs in the convalescent phase of SD. Note the  564
lack of reactivity with the P-H17 N-terminal, and the cross-reactivity of normal pig sera  565
with some of the proteins. 566
567
Fig. 2. Comparison of temporal changes in serum antibody concentrations in ELISA to the  568
four recombinant B. hyodysenteriae proteins and a whole cell preparation in control and  569
vaccinated pigs. 570
571
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Table 1. Mean and standard deviation of group colonic antibody levels (OD values) to 
different ELISA antigens at post-mortem.
ELISA antigen Antibody 
class
Group
a  OD value  P value in t 
test
P-H7  lgA 1 0.50 ± 0.27 0.077
2 0.75 ± 0.28
IgG 1 0.48 ± 0.24 0.125
2 0.66 ± 0.25
P-H17, N-
terminal 
lgA 1 0.32 ± 0.14 0.007
2 0.69 ± 0.29
IgG 1 0.32 ± 0.13 0.018
2 0.56 ± 0.21
P-H34  IgA 1 0.42 ± 0.13 0.006
2 0.72 ± 0.22
IgG 1 0.45 ± 0.14 0.038
2 0.61 ± 0.15
P-H42 IgA 1 0.50 ± 0.18 0.003
2 0.84 ± 0.20
IgG 1 0.45 ± 0.14 0.023
2 0.67 ± 0.20
Whole-cell IgA 1 0.38 ± 0.14 0.016
2 0.74 ± 0.21
IgG 1 0.56 ± 0.36 0.305
2 0.71 ± 0.24
a Group 1, non-vaccinated control; group 2, vaccinated.
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Table 2. 
Clinical signs and post-mortem B. hyodysenteriae culture results and colonic lesions in 
experimental pigs, including the cumulative clinical + lesion score.
Post-mortem culture
c
Pig
a Clinical signs
b Faeces Caecum Colon Lesion severity
C1 Dys + + + Severe
C2 Dys - - - Mild
C3 EOE + + + Normal
C4 Dys + + + Severe
C5 Dys + + + Severe
C6 EOE - - - Normal
C7 EOE - + + Normal
C8 Dys + + + Severe
C9 EOE + - - Normal
V1 EOE - - - Normal
V2 EOE - + + Normal
V3 Dys + + + Mild
V4 EOE - + - Normal
V5 EOE - + - Normal
V6 EOE + + + Normal
V7 EOE + + + Mild
V8 EOE + + + Normal
aC1-9: non-vaccinated pigs; V1-8: vaccinated pigs. 
bDys; dysentery observed and the pig killed; EOE; end of experiment (no dysentery 
observed). 
c+ indicates B. hyodysenteriae culture positive, - indicates B. hyodysenteriae culture 
negative.
Table2